Report
Nyxoah - A crucial year ahead
No major surprises in this update as Nyxoah published preliminary results early January. Overall, results are in line with our estimates and CSS. Q4 was the strongest quarter in Nyxoah's history, also helped by a seasonality effect. Remember that the US remains the biggest value driver.Nyxoah is at a turning point in its history. Two major catalysts expected in 2024 with 1/ the publication of the top-line results from its US pivotal DREAM trial in c. 1 month and 2/ FDA approval foreseen by year end. Keep in mind that the DREAM trial is already quite de-risked following positive interim-data,
Underlying
Nyxoah
Provider
Degroof Petercam
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Laura Roba
Other Reports on these Companies
Other Reports from Degroof Petercam
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.